Evusheld procurement plan gets CCSA approvalThe Centre for Covid-19 Situation Administration (CCSA) has approved a plan to procure a long-acting coronavirus antibody cocktail for people with poor immune systems who cannot be vaccinated. Government spokesman Thanakorn Wangboonkongchana said the drug, branded as Evusheld, was developed by AstraZeneca and registered in June last year. Speaking after a CCSA meeting on Friday, Mr Thanakorn said the Office of the Attorney-General has advised the government to amend the vaccine procurement contract with AstraZeneca to replace some of the vaccine doses with Evusheld. So far, some 3.1 million kits have already been handed out to 1.2 million people, he said. "The prime minister has applauded the move and asked them to consider the possibility of increasing the output to 1 million kits a month," he said.

Source: Bangkok Post April 10, 2022 21:50 UTC